Literature DB >> 12563701

Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis.

Suzanne L Bowyer1, Philip A Roettcher, Gloria C Higgins, Barbara Adams, Linda K Myers, Carol Wallace, Robert Rennebohm, Terry L Moore, Peri H Pepmueller, Charles Spencer, Linda Wagner-Weiner, Egla Rabinovich, Murray Passo, Daniel J Lovell, Deborah McCurdy, Lawrence Zemel, Kenneth N Schikler, Ilona Szer, Paul Kurtin, Carol Lindsley.   

Abstract

OBJECTIVE: To describe the health and functional status of children with juvenile rheumatoid arthritis (JRA) diagnosed in the early 1990s.
METHODS: Patients were obtained from the Pediatric Rheumatology Disease Registry, a database of patients seen in pediatric rheumatology centers across the United States. Questionnaires designed to be filled out after retrospective chart review were sent to pediatric rheumatologists caring for children diagnosed with JRA between 1992 and 1997.
RESULTS: We studied 703 patients -- 376 with pauciarticular onset (pauci), 232 with polyarticular onset (poly), and 95 with systemic onset JRA (systemic). At 1 year after diagnosis, half of the pauci and systemic patients no longer required medication, compared to 78% of the poly patients; 98% of the patients functioned in Steinbrocker classes I and II. Six percent of pauci, 27% of poly, and 11% of systemic patients had limitations in school function. Nearly 1/3 of poly patients already had joint space narrowing on radiograph. By 5 years after diagnosis, all pauci, 88% of poly, and 70% of systemic patients were in Steinbrocker classes I and II; but 6% of pauci, 28% of poly, and 44% of systemic patients had limitations in school function. Nearly 2/3 of poly and systemic patients had joint space narrowing.
CONCLUSION: In these children treated prior to the era of biologic therapy, at 5 years after onset, > 25% of poly and nearly half of systemic patients had functional limitations that required modifications in their school schedule. Radiographically evident joint space damage was seen within a year of onset in poly patients, and by 5 years 2/3 of poly and systemic patients had damage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12563701

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  31 in total

Review 1.  Diagnosis and management of adult onset Still's disease.

Authors:  P Efthimiou; P K Paik; L Bielory
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

2.  Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states.

Authors:  Claudia Macaubas; Khoa Nguyen; Chetan Deshpande; Carolyn Phillips; Ariana Peck; Tzielan Lee; Jane L Park; Christy Sandborg; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2009-10-29       Impact factor: 3.969

3.  Sleep Fragmentation and Biomarkers in Juvenile Idiopathic Arthritis.

Authors:  Teresa M Ward; Weichao Yuwen; Joachim Voss; Dirk Foell; Faekah Gohar; Sarah Ringold
Journal:  Biol Res Nurs       Date:  2015-10-27       Impact factor: 2.522

4.  Laryngeal involvement in juvenile idiopathic arthritis patients.

Authors:  Mosaad Abdel-Aziz; Noha A Azab; Iman H Bassyouni; Gehan Hamdy
Journal:  Clin Rheumatol       Date:  2011-05-26       Impact factor: 2.980

5.  Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.

Authors:  Thita Pacharapakornpong; Sakda Arj-Ong Vallibhakara; Butsabong Lerkvaleekul; Soamarat Vilaiyuk
Journal:  Rheumatol Int       Date:  2016-10-31       Impact factor: 2.631

6.  Articular damage in adults with juvenile idiopathic arthritis.

Authors:  Eda Gurcay; Emel Eksioglu; Serdil Yuzer; Ajda Bal; Aytul Cakci
Journal:  Rheumatol Int       Date:  2008-10-14       Impact factor: 2.631

7.  Longitudinal growth attainments of Indian boys with juvenile rheumatoid arthritis.

Authors:  Bimal Aggarwal; Anil K Bhalla; Surjit Singh
Journal:  Rheumatol Int       Date:  2010-01-07       Impact factor: 2.631

8.  Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.

Authors:  Anthony C Gregory; John H Kempen; Ebenezer Daniel; R Oktay Kaçmaz; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne
Journal:  Ophthalmology       Date:  2012-10-11       Impact factor: 12.079

9.  Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.

Authors:  Marion A J van Rossum; Renée M van Soesbergen; Maarten Boers; Aeilko H Zwinderman; Theo J W Fiselier; Marcel J A M Franssen; Rebecca ten Cate; Lisette W A van Suijlekom-Smit; Nico M Wulffraat; Wilma H J van Luijk; Johanna C M Oostveen; Wietse Kuis; Ben A C Dijkmans
Journal:  Ann Rheum Dis       Date:  2007-05-09       Impact factor: 19.103

10.  Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study.

Authors:  Kimme L Hyrich; Sham D Lal; Helen E Foster; Judith Thornton; Navid Adib; Eileen Baildam; Janet Gardner-Medwin; Lucy R Wedderburn; Alice Chieng; Joyce Davidson; Wendy Thomson
Journal:  Rheumatology (Oxford)       Date:  2009-11-19       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.